Sahajanand Medical Technologies (NSE: SMT, BSE: 545001) is a Surat, Gujarat-based company in the Medical Consumables industry. With a market capitalisation of ₹4,899 Cr, it ranks #843 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 14 in Medical Consumables. At ₹538.85 (as of 19 Nov 2026), the share price is 6.8% below its 52-week high of ₹578.10 and 55.1% above its 52-week low of ₹347.50.
| Current Price | ₹538.85 |
|---|---|
| Market Cap | ₹4,899 Cr |
| NSE Symbol | SMT |
| BSE Code | 545001 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies |
| Sub-Industry | Health Care Supplies > Medical Consumables |
| P/E Ratio | 77.9 |
| Return on Assets | 5.79% |
| 52-Week Range | ₹347.50 – ₹578.10 |
| Beta (1Y) | 2.62 |
| Headquarters | Surat, Gujarat |
| Website | www.smtpl.com |
| Revenue | ₹373 Cr |
|---|---|
| Net Profit | ₹26 Cr |
| Net Margin | 7.1% |
| EPS (Basic) | ₹2.63 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 36.20% of Sahajanand Medical Technologies's shares as of Oct 2026. Delivery averaged 24.2% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Sahajanand Medical Technologies Limited engages in the manufacture and distribution of Class III and Class C/D medical devices in India, Europe, rest of the Asia Pacific, Latin America, and the Middle East and Africa. The company provides vascular intervention products coronary stents and balloons used to diagnose or treat diseases of the blood vessels; structural heart products comprising trans-catheter aortic valves and occluders used to treat defects or abnormalities in the heart’s structure; and other products, such as renal stents, peripheral drug-coated balloon catheters, and other trading products. It also trades in and distributes medical devices/medical implants; and surgical, hospital, pharmaceutical, dental, laboratory, and orthopedic and traumatology products, materials, and equipment. The company was founded in 1999 and is headquartered in Surat, India.
1. Cardiovascular Devices-This segment offers cardiovascular devices. 2. NA-NA 3. NA-NA 4. NA-NA
1. Cardiovascular Devices-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Poly Medicure Ltd. | ₹17,162 Cr | 53.3 | 10.84% | ₹581 Cr | -14.5% |
| Sahajanand Medical Technologies | ₹4,899 Cr | 77.9 | — | ₹373 Cr | — |
| Q-Line Biotech Limited | ₹1,280 Cr | 15.7 | 22.63% | — | — |
| Laxmi Dental Limited | ₹1,128 Cr | 39.3 | 12.77% | ₹80 Cr | -38.2% |
| Prevest Denpro Ltd | ₹502 Cr | 24.6 | 17.79% | — | -22.6% |
| Choksi Imaging Ltd. | ₹119 Cr | 22.3 | 13.51% | — | +94.0% |
| GSM Foils Limited | ₹72 Cr | 3.9 | 37.54% | ₹97 Cr | -78.3% |
| Mohini Health & Hygiene Ltd | ₹51 Cr | n/m | -17.18% | — | -41.2% |
| KMS Medisurgi Limited | ₹46 Cr | 188.4 | — | — | +4.7% |
Listed by market capitalisation. Ratios are shown for context only.
Sahajanand Medical Technologies is trading at ₹538.85, with a market capitalisation of ₹4,899 Cr.
Sahajanand Medical Technologies operates in the Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies space (Health Care Supplies > Medical Consumables).
Sahajanand Medical Technologies has a P/E of 77.9.
Sahajanand Medical Technologies is listed on the NSE under the symbol SMT and on the BSE under the scrip code 545001.
In Q2 FY27, Sahajanand Medical Technologies reported revenue of ₹373 Cr and net profit of ₹26 Cr, with basic EPS of ₹2.63 (consolidated, parsed from the company's exchange filing).
Promoters held 36.20% of Sahajanand Medical Technologies's shares as of Oct 2026.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.